KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $5.2 million.

  • Sarepta Therapeutics' Gains from Investment Securities rose 19360.4% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 7119.64%. This contributed to the annual value of $8.9 million for FY2024, which is 728.63% down from last year.
  • As of Q3 2025, Sarepta Therapeutics' Gains from Investment Securities stood at $5.2 million, which was up 19360.4% from -$4.6 million recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Gains from Investment Securities ranged from a high of $36.8 million in Q4 2024 and a low of -$5.5 million during Q3 2024
  • Over the past 5 years, Sarepta Therapeutics' median Gains from Investment Securities value was $816855.5 (recorded in 2021), while the average stood at $3.4 million.
  • In the last 5 years, Sarepta Therapeutics' Gains from Investment Securities soared by 3590649.35% in 2022 and then crashed by 58768.82% in 2024.
  • Over the past 5 years, Sarepta Therapeutics' Gains from Investment Securities (Quarter) stood at $77000.0 in 2021, then skyrocketed by 35906.49% to $27.7 million in 2022, then tumbled by 98.71% to $357000.0 in 2023, then skyrocketed by 10205.6% to $36.8 million in 2024, then plummeted by 85.89% to $5.2 million in 2025.
  • Its Gains from Investment Securities was $5.2 million in Q3 2025, compared to -$4.6 million in Q2 2025 and $1.5 million in Q1 2025.